TY - JOUR
T1 - An International Perspective on Preceding Infections in Guillain-Barré Syndrome
T2 - The IGOS-1000 Cohort
AU - Leonhard, Sonja E
AU - van der Eijk, Annemiek A
AU - Andersen, Henning
AU - Antonini, Giovanni
AU - Arends, Samuel
AU - Attarian, Shahram
AU - Barroso, Fabio A
AU - Bateman, Kathleen J
AU - Batstra, Manou R
AU - Benedetti, Luana
AU - van den Berg, Bianca
AU - Van den Bergh, Peter
AU - Bürmann, Jan
AU - Busby, Mark
AU - Casasnovas, Carlos
AU - Cornblath, David R
AU - Davidson, Amy
AU - Doets, Alex Y
AU - van Doorn, Pieter A
AU - Dornonville de la Cour, Charlotte
AU - Feasby, Thomas E
AU - Fehmi, Janev
AU - Garcia-Sobrino, Tania
AU - Goldstein, Jonathan M
AU - Gorson, Kenneth C
AU - Granit, Volkan
AU - Dm Hadden, Robert
AU - Harbo, Thomas
AU - Hartung, Hans-Peter
AU - Hasan, Imran
AU - Holbech, Jakob V
AU - Holt, James Kl
AU - Jahan, Israt
AU - Islam, Zhahirul
AU - Karafiath, Summer
AU - Katzberg, Hans D
AU - Kleyweg, Ruud P
AU - Kolb, Noah
AU - Kuitwaard, Krista
AU - Kuwahara, Motoi
AU - Kusunoki, Susumu
AU - Luijten, Linda W G
AU - Kuwabara, Satoshi
AU - Lee Pan, Edward
AU - Lehmann, Helmar C
AU - Maas, Marijke
AU - Martín-Aguilar, Lorena
AU - Miller, James Al
AU - Mohammad, Quazi Deen
AU - Sindrup, Søren Hein
AU - IGOS Consortium
N1 - © 2022 American Academy of Neurology.
PY - 2022/9/20
Y1 - 2022/9/20
N2 - BACKGROUND AND OBJECTIVES: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.METHODS: We analysed the first 1000 patients included in the International GBS Outcome Study with available biosamples (n=768) for the presence of a recent infection with: Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus.RESULTS: Serological evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%) and Epstein-Barr virus in 7 (1%) patients. Evidence of more than one recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiological subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni-positive patients were more severely affected, indicated by a lower MRC sum score at nadir (P=0.004), and a longer time to regain the ability to walk independently (P=0.005). The pure motor variant and axonal electrophysiological subtype were more frequent in Asian compared to American or European C. jejuni-positive patients (P<0.001, resp. P= 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (P=0.004).CONCLUSION: Across geographical regions, the distribution of infections was similar but the association between infection and clinical phenotype differed. A mismatch between symptom reporting and serological results and the high frequency of co-infections, demonstrate the importance of broad serological testing in identifying the most likely infectious trigger. The association between infections and outcome indicates their value for future prognostic models.
AB - BACKGROUND AND OBJECTIVES: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.METHODS: We analysed the first 1000 patients included in the International GBS Outcome Study with available biosamples (n=768) for the presence of a recent infection with: Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus.RESULTS: Serological evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%) and Epstein-Barr virus in 7 (1%) patients. Evidence of more than one recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiological subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni-positive patients were more severely affected, indicated by a lower MRC sum score at nadir (P=0.004), and a longer time to regain the ability to walk independently (P=0.005). The pure motor variant and axonal electrophysiological subtype were more frequent in Asian compared to American or European C. jejuni-positive patients (P<0.001, resp. P= 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (P=0.004).CONCLUSION: Across geographical regions, the distribution of infections was similar but the association between infection and clinical phenotype differed. A mismatch between symptom reporting and serological results and the high frequency of co-infections, demonstrate the importance of broad serological testing in identifying the most likely infectious trigger. The association between infections and outcome indicates their value for future prognostic models.
KW - Campylobacter Infections/complications
KW - Epstein-Barr Virus Infections/complications
KW - Guillain-Barre Syndrome/diagnosis
KW - Herpesvirus 4, Human
KW - Humans
KW - Internationality
U2 - 10.1212/WNL.0000000000200885
DO - 10.1212/WNL.0000000000200885
M3 - Journal article
C2 - 35981895
SN - 0028-3878
VL - 99
SP - e1299-e1313
JO - Neurology
JF - Neurology
IS - 12
ER -